An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines in the US under new Health and Human Services (HHS) Secretary Robert F ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...